[Pharmacokinetic and clinical evaluations of flomoxef in neonates]. 1991

T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
Department of Pediatrics, Mie National Hospital.

To evaluate pharmacokinetics and clinical efficacy of flomoxef (6315-S, FMOX) in neonates, FMOX was administered to 21 neonates. With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively. When 45-100 mg/kg of FMOX was administered to 17 neonates with infections (pneumonia 8, sepsis 1, sepsis suspected 2, intrauterine infection 2, urinary tract infection 2, omphalitis 2), the efficacy rate was 88.2% (15 of 17). No adverse reactions were observed clinically in the 21 neonates. Transient elevation of eosinophilia was observed in 1 case and transient elevation of S-GOT and S-GPT 1 in another. These results suggest that FMOX is an effective and safe antibiotic to use in neonates.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic

Related Publications

T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
November 1991, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
November 1991, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
March 1988, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
July 1993, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
March 1988, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
November 1991, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
October 1987, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
March 1988, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
June 1991, The Japanese journal of antibiotics,
T Ihara, and H Kamiya, and T Matsuda, and S Shimizu, and H Nishi, and H Inamochi, and N Taki, and M Suzuki, and M Kojima, and H Kawasaki
November 1991, The Japanese journal of antibiotics,
Copied contents to your clipboard!